Florence Abravanel1, Sébastien Lhomme2, Mélanie Fougère2, Karine Saune2, Muriel Alvarez3, Jean-Marie Péron4, Pierre Delobel5, Jacques Izopet2. 1. Centre de Physiopathologie de Toulouse Purpan, INSERM U1043/CNRS UMR5282/Université Toulouse III Paul-Sabatier, F-31024, Toulouse, France; CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, Centre National de Référence Hépatite E, Institut Fédératif de Biologie, F-31300, Toulouse, France. Electronic address: abravanel.f@chu-toulouse.fr. 2. Centre de Physiopathologie de Toulouse Purpan, INSERM U1043/CNRS UMR5282/Université Toulouse III Paul-Sabatier, F-31024, Toulouse, France; CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, Centre National de Référence Hépatite E, Institut Fédératif de Biologie, F-31300, Toulouse, France. 3. CHU Toulouse, Hôpital Purpan, Service des maladies infectieuses et tropicales, F-31049, Toulouse, France. 4. CHU Toulouse, Hôpital Purpan, Service de Gastroentérologie, F-31300, Toulouse, France. 5. Centre de Physiopathologie de Toulouse Purpan, INSERM U1043/CNRS UMR5282/Université Toulouse III Paul-Sabatier, F-31024, Toulouse, France; CHU Toulouse, Hôpital Purpan, Service des maladies infectieuses et tropicales, F-31049, Toulouse, France.
Abstract
OBJECTIVES: The reported prevalence of anti-hepatitis E virus antibodies in HIV-positive patients from industrialized countries varies greatly. It is also difficult to compare these data with the anti-IgG prevalence in the general population because age and sex are not matched in most studies. Moreover, MSM are at increased risk of viral hepatitis. METHODS: HEV is endemic in southwestern France. We investigated therefore 300 HIV-infected patients consecutively attending the out-patient clinic of Toulouse University Hospital. Each HIV-infected patient was matched for sex and age with 2 healthy blood donors from the same area. They were tested for anti-HEV IgM and IgG. RESULTS: Anti-HEV IgG was found in 116 HIV-infected patients (38.7%) and in 284 matched controls (47.3%, p = 0.027). However, anti-HEV IgG concentration tended to be lower in HIV-patients than in controls. Anti-HEV IgM prevalence was similar HIV-infected patients (3.6%) and in matched controls (3.8%, p = 0.85). CONCLUSION: The prevalence and concentrations of anti-HEV IgG in HIV-infected patients from Southern-France were lower than in controls, suggesting a weaker humoral response. But their prevalences of anti-HEV IgM were similar, indicating a high incidence of HEV infection. These data do not indicate that HEV is transmitted sexually.
OBJECTIVES: The reported prevalence of anti-hepatitis E virus antibodies in HIV-positivepatients from industrialized countries varies greatly. It is also difficult to compare these data with the anti-IgG prevalence in the general population because age and sex are not matched in most studies. Moreover, MSM are at increased risk of viral hepatitis. METHODS: HEV is endemic in southwestern France. We investigated therefore 300 HIV-infectedpatients consecutively attending the out-patient clinic of Toulouse University Hospital. Each HIV-infectedpatient was matched for sex and age with 2 healthy blood donors from the same area. They were tested for anti-HEV IgM and IgG. RESULTS: Anti-HEV IgG was found in 116 HIV-infectedpatients (38.7%) and in 284 matched controls (47.3%, p = 0.027). However, anti-HEV IgG concentration tended to be lower in HIV-patients than in controls. Anti-HEV IgM prevalence was similar HIV-infectedpatients (3.6%) and in matched controls (3.8%, p = 0.85). CONCLUSION: The prevalence and concentrations of anti-HEV IgG in HIV-infectedpatients from Southern-France were lower than in controls, suggesting a weaker humoral response. But their prevalences of anti-HEV IgM were similar, indicating a high incidence of HEV infection. These data do not indicate that HEV is transmitted sexually.
Authors: Jeanne Heil; Christian J P A Hoebe; Inge H M van Loo; Jochen W L Cals; Geneviève A F S van Liere; Nicole H T M Dukers-Muijrers Journal: PLoS One Date: 2018-01-25 Impact factor: 3.240